Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Next Previous
Trial Profile

A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilobelimab (Primary) ; Cyclophosphamide; Prednisone; Rituximab
  • Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IXchange
  • Sponsors InflaRx

    • Most Recent Events

    • 14 Nov 2022 Results presented at the ACR Convergence 2022
    • 15 Nov 2021 Results published in the InflaRx Media Release
    • 15 Nov 2021 According to an InflaRx media release, the company plans to discuss the data from both the US and EU studies with regulatory authorities to determine next steps with the program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top